Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL)

被引：0

作者：

Piekarz, Richard ^{[1
]}

Wright, John ^{[2
]}

Frye, Robin ^{[1
]}

Allen, Steven L. ^{[3
]}

Craig, Michael ^{[4
]}

Geskin, Larisa ^{[5
]}

Hutchins, Laura ^{[6
]}

Joske, David ^{[7
]}

Kirschbaum, Mark ^{[8
]}

Leonard, John P. ^{[9
]}

Prince, Miles ^{[10
]}

Reeder, Craig B. ^{[11
]}

Jaffe, Elaine ^{[1
]}

Bates, Susan ^{[12
]}

机构：

[1] NCI, Bethesda, MD 20892 USA

[2] IDB CTEP NCI, Rockville, MD USA

[3] N Shore Univ, Hosp LIJ, Lake Success, NY USA

[4] Mary Babb Randolph Canc Ctr, Morgantown, WV USA

[5] Univ Pittsburgh, Pittsburgh, PA USA

[6] Univ Arkansas Med Sci, Little Rock, AR 72205 USA

[7] Sir Charles Gairdner Hosp, Haematol Care Ctr, Perth, WA, Australia

[8] City Hope Natl Med Ctr, Div Hematol, Duarte, CA 91010 USA

[9] Weill Cornell Med Coll, New York, NY USA

[10] Peter MacCallum Canc Inst, Melbourne, Australia

[11] Mayo Clin Arizona, Scottsdale, AZ USA

[12] NCI, Bethesda, MD 20892 USA

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：555 / 556

页数：2

共 50 条

[31] Romidepsin for peripheral T-cell lymphoma
Khot, Amit
Dickinson, Michael
Prince, H. Miles
EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (04) : 351 - 359
[32] Phase I Study of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
Chihara, Dai
Oki, Yasuhiro
Fayad, Luis
Wesson, Emily
Ruben, Charnelle
Horowitz, Sandra B.
Woolery, Joseph
Feng, Lei
Garg, Naveen
Ahmed, Sairah
Khouri, Issa F.
Fanale, Michelle A.
BLOOD, 2014, 124 (21)
[33] Romidepsin Is Effective and Well-Tolerated in Patients >= 60 Years Old With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis From Phase 2 Trials Commentary
Horwitz, Steven M.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (02) : 19 - 22
[34] Final Analysis of the RO-CHOP Phase Ib/II Study: Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL)
Dupuis, Jehan
Morschhauser, Franck
Ghesquieres, Herve
Tilly, Herve
Casasnovas, Olivier
Amorim, Sandy
Ribrag, Vincent
Coiffier, Bertrand
BLOOD, 2014, 124 (21)
[35] PERIPHERAL T-CELL LYMPHOMA PTCL
Hamed, Hanan
LEUKEMIA RESEARCH, 2017, 61 : S10 - S11
[36] Correction to: Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma
Dai Maruyama
Kunihiro Tsukasaki
Toshiki Uchida
Yoshinobu Maeda
Hirohiko Shibayama
Hirokazu Nagai
Mitsutoshi Kurosawa
Yoko Suehiro
Kiyohiko Hatake
Kiyoshi Ando
Isao Yoshida
Michihiro Hidaka
Tohru Murayama
Yoko Okitsu
Norifumi Tsukamoto
Masafumi Taniwaki
Junji Suzumiya
Kazuo Tamura
Takahiro Yamauchi
Ryuzo Ueda
Kensei Tobinai
Annals of Hematology, 2018, 97 : 2529 - 2530
[37] Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma
Piekarz, R.
Frye, R.
Wright, J.
Figg, W.
Allen, S.
Kirschbaum, M.
Zain, J.
Hutchins, L.
Showe, L.
Fojo, T.
Bates, S. E.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[38] A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
Cinzia Pellegrini
Anna Dodero
Annalisa Chiappella
Federico Monaco
Debora Degl’Innocenti
Flavia Salvi
Umberto Vitolo
Lisa Argnani
Paolo Corradini
Pier Luigi Zinzani
Journal of Hematology & Oncology, 9
[39] A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
Pellegrini, Cinzia
Dodero, Anna
Chiappella, Annalisa
Monaco, Federico
Degl'Innocenti, Debora
Salvi, Flavia
Vitolo, Umberto
Argnani, Lisa
Corradini, Paolo
Zinzani, Pier Luigi
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
[40] Romidepsin for the Treatment of Peripheral T-Cell Lymphoma
Iyer, Swaminathan P.
Foss, Francine F.
ONCOLOGIST, 2015, 20 (09): : 1084 - 1091

← 1 2 3 4 5 →